Antibiotic Stewardship 2026: Resistance Trends and Empiric Therapy Updates
Sam Anderson
The Resistance Crisis: 2026 Epidemiology
Antimicrobial resistance is not a future threat — it is a current clinical reality that affects prescribing decisions every day. The hospitalist choosing empiric therapy for a complex urinary tract infection, the emergency physician covering for possible MRSA pneumonia, and the intensivist selecting an agent for a critically ill patient with prior multidrug-resistant organism colonization are all navigating the consequences of resistance in real time. Stewardship is not an abstract public health concept. It is the framework that helps clinicians make better antibiotic choices for the patient in front of them today while preserving the efficacy of these agents for the patient who will need them tomorrow.
Antimicrobial resistance (AMR) accounts for an estimated 1.27 million deaths annually worldwide and contributes to 4.95 million deaths[1]. In the United States (see also neonatal sepsis empiric therapy), carbapenem-resistant Enterobacterales (CRE), extended-spectrum beta-lactamase (ESBL) producers, and methicillin-resistant Staphylococcus aureus (MRSA) remain the most clinically significant resistant organisms.
Empiric Therapy Updates: What Changed
Updated IDSA guidelines recommend ceftriaxone plus metronidazole (instead of fluoroquinolones) for complicated intra-abdominal infections. For community-acquired pneumonia requiring hospitalization, the combination of beta-lactam plus macrolide remains first-line, with respiratory fluoroquinolone monotherapy reserved as an alternative. Empiric MRSA coverage should be considered when local MRSA prevalence exceeds 20% or in patients with prior MRSA history.
The Fluoroquinolone De-prioritization
The shift away from fluoroquinolones as first-line agents for intra-abdominal infections reflects both rising resistance rates and accumulating safety concerns. Fluoroquinolone resistance among E. coli — the most common gram-negative pathogen in intra-abdominal and urinary infections — has increased steadily over the past decade, and community-acquired fluoroquinolone resistance now exceeds 20% in many US regions. Simultaneously, the FDA has progressively strengthened warnings about fluoroquinolone-associated toxicities: tendon rupture, peripheral neuropathy, aortic dissection, and central nervous system effects. Ceftriaxone plus metronidazole provides equivalent coverage with a better safety profile and lower resistance pressure. The practical implication for prescribers is straightforward: fluoroquinolones are no longer the default choice for most common infections, and should be reserved for situations where alternatives are genuinely unsuitable.
Knowing Your Local Antibiogram
No national guideline can replace familiarity with your institution's antibiogram. The MRSA prevalence threshold of 20% for adding empiric coverage is a useful benchmark, but the actual decision should be informed by local data. If your hospital's antibiogram shows E. coli fluoroquinolone resistance at 35%, the fluoroquinolone is not a reliable empiric choice regardless of what any guideline says about it being an "alternative." Similarly, if your institution's ESBL-producing Enterobacterales rate has risen above 10-15% in urine cultures, empiric piperacillin-tazobactam for complicated urinary tract infections may no longer be adequate, and carbapenem or alternative agents should be considered. The antibiogram should be reviewed at least annually and should inform every empiric prescribing decision, particularly for hospitalized patients.
Rapid Diagnostics: Changing the Paradigm
Rapid molecular diagnostic platforms (BioFire FilmArray, Accelerate Pheno, T2Biosystems) provide pathogen identification and resistance gene detection within 1-6 hours, compared to 48-72 hours for conventional culture[2] and susceptibility. Studies demonstrate that coupling rapid diagnostics with antimicrobial stewardship programs reduces time to appropriate therapy by 12-24 hours and decreases mortality in bacteremia[3].
Making Rapid Diagnostics Actionable
The key insight from the rapid diagnostics literature is that the technology alone does not improve outcomes — it is the combination of rapid results with stewardship-driven clinical action that produces the benefit. A blood culture panel that identifies MRSA within 2 hours is only useful if there is a system in place to notify the treating clinician, an infectious disease pharmacist or physician to recommend targeted therapy, and a mechanism to ensure the recommendation is implemented promptly. Institutions that have deployed rapid diagnostics without concurrent stewardship infrastructure have seen minimal improvement in time to appropriate therapy. The technology is the enabler; the clinical workflow is the intervention.
De-escalation and Duration Optimization
Antibiotic stewardship increasingly focuses on shorter treatment durations based on recent evidence. Community-acquired pneumonia: 3-5 days (versus traditional 7-10). Uncomplicated cellulitis: 5-6 days. Urinary tract infection: 3-5 days for uncomplicated cystitis, 5-7 days for uncomplicated pyelonephritis. Procalcitonin-guided de-escalation reduces antibiotic duration by 2-3 days in respiratory infections and sepsis without adverse outcomes. Prolonged antibiotic use is a key risk factor for C. difficile infection.
Overcoming the "Finish the Course" Mindset
One of the most persistent barriers to implementing shorter antibiotic durations is the deeply ingrained clinical instinct — and patient expectation — to "finish the course." Generations of clinicians and patients were taught that stopping antibiotics early promotes resistance, but the evidence increasingly shows the opposite: unnecessarily prolonged courses select for resistance more than appropriately shortened ones. The clinician's role is to prescribe the shortest effective duration supported by the evidence and to set clear expectations at the time of prescribing. Telling a patient at discharge "you'll take this antibiotic for 5 days" is more effective than telling them "take it for 10 days and we might call to shorten it." Clear, confident communication about evidence-based duration at the point of prescribing prevents the confusion and anxiety that arise when courses are shortened mid-treatment.
Procalcitonin: When to Use It and When Not To
Procalcitonin-guided de-escalation has the strongest evidence in lower respiratory tract infections and sepsis, where serial procalcitonin measurements can safely guide antibiotic discontinuation. The general principle is that a procalcitonin level that has declined by 80% or more from its peak, or has dropped below 0.25-0.5 ng/mL, supports safe discontinuation. However, procalcitonin is not useful for all infections: it is unreliable in patients with chronic kidney disease (where it may be persistently elevated), in localized infections without systemic inflammation (where it may remain low despite active infection), and in certain populations where the kinetics are poorly characterized. Like any biomarker, procalcitonin is a decision-support tool that supplements clinical judgment rather than replacing it.
Building a Stewardship Culture
The most effective antibiotic stewardship programs succeed not because of restrictive formulary policies or punitive audits, but because they change prescriber behavior through education, feedback, and culture. The clinician who understands why ceftriaxone is preferred over levofloxacin for intra-abdominal infections — not just that a guideline says so — is more likely to make that choice consistently. Prospective audit with feedback, in which stewardship pharmacists review antibiotic orders and provide individualized recommendations, has been shown to reduce broad-spectrum antibiotic use while improving clinical outcomes. The goal is not to prevent clinicians from prescribing antibiotics but to help them prescribe the right antibiotic, at the right dose, for the right duration, for the right infection.
Limitations and Ongoing Challenges
Despite progress, significant challenges remain. Outpatient antibiotic prescribing — which accounts for the majority of antibiotic use — is far less amenable to institutional stewardship interventions than inpatient prescribing. Rapid diagnostic availability is concentrated in academic medical centers and large community hospitals, leaving smaller facilities and outpatient settings without these tools. And the pipeline of novel antibiotics targeting resistant gram-negative organisms remains worryingly thin, with economic incentives for antibiotic development fundamentally misaligned with the clinical need. Stewardship is not a one-time project but an ongoing discipline that requires sustained institutional commitment, clinician engagement, and resources.
References
Frequently Asked Questions
What are the updated empiric therapy recommendations for intra-abdominal infections?
How do rapid diagnostics improve antibiotic stewardship?
What are the evidence-based shorter antibiotic durations?
When should empiric MRSA coverage be added?
What is the global burden of antimicrobial resistance?
Explore This Topic in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
Founder of Ailva.ai | Former Director of Research and Author of 200+ Medically Reviewed Articles | Editor-in-Chief of EudaLife Magazine